Use of Multispectral Digital Skin Lesion Analysis for Evaluation of Nevi in Children
October 2014 | Volume 13 | Issue 10 | Original Article | 1269 | Copyright © 2014
Andrew S. Dorizas MD,a Amer H. Nassar MD,a and David J. Goldberg MDb,c
aSadick Dermatology, New York, NY
bMount Sinai School of Medicine, New York, NY
cSkin Laser and Surgery Specialists of NY/NJ, New York, NY
OBJECTIVE: We determine if the use of Multispectral Digital Skin Lesion Analysis for the evaluation of nevi in children and possible detection of malignancies.
EVIDENCE REVIEW: Evidence gathered from a pivotal study involving 1,383 patients with 1,831-pigmented lesions. The isolated use of the pediatric population within this study was used to determine the specificity and sensitivity of such a device with comparison to a dermatologists evaluation.
FINDINGS: For all lesions from the assessed pediatric population the biopsy ratio was equivalent for the Multispectral Digital Skin Lesion Analysis device as for the dermatologists when performing as independent reviewers. Furthermore analyzed data suggests that dermatologists who incorporate the Multispectral Digital Skin Lesion Analysis device perform better than they would independently or if they were to follow the device blindly without incorporating their own judgment.
CONCLUSION AND RELEVANCE: An approach that integrates automated imaging technology like the Multispectral Digital Skin Lesion Analysis device, along with another diagnostic aid, with the end result being cost-effective, easy to use by even non-experts and comforting for the pediatric patient is likely to compete to be the new gold standard in successful early diagnosis and management of melanoma.
J Drugs Dermatol. 2014;13(10):1269-1273.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
Melanoma is a rare yet deadly disease in the pediatric population, and often has distinct clinical attributes compared with adult melanoma. Data from the Surveillance, Epidemiology, and End Results (SEER) program shows an overall steady increase in pediatric melanoma by approximately 2% per year.1,2,3 Childhood melanoma is more common in boys and most often presents in the face and trunk, whereas adolescent girls are at increased risk for a more distal manifestation, specifically in the lower extremities and hips.4 Melanoma has a multifactorial causality and is associated with genetic and environmental factors, including sun exposure, Fitzpatrick pigmentation phenotype, large congenital nevi, familial melanoma and autoimmune diseases.5,6,7
The risk of malignant degeneration in small and medium congenital nevi is exceedingly minimal and does not warrant any clinical intervention. In contrast the risk of melanoma in large or giant congenital nevi is estimated to be 2-5% over lifetime, with a significant risk during the first decade of life.8 The total number of acquired melanocytic nevi on the body is an important risk factor for melanoma. The risk of melanoma is directly proportional to the increase in number of nevi.9 Dysplastic nevi are distinguished on the basis of histological features and are considered to be a marker for an increased risk for the development of melanoma.10,11 Finally, Spitz nevi are a variant of acquired melanocytic nevi, presenting as a small pink to red papules on the face, considered benign, yet a minority may exhibit clinical and histological atypia, featuring risk for melanoma.12
The frontline of melanocytic nevi management relies on patient and caregiver education. It includes both preventative measures and instructions for routine skin evaluation.13,14 However, it is important to note that in the pediatric population clinical characteristics do not always follow the typical “ABCDE” detection criteria. Pediatric melanoma characteristics are amelanosis, bleeding, color uniformity, diameter variability, and de novo development. Certain studies estimate that the ABCD screening system fails to recognize 60% of childhood and 40% of adolescent melanomas.15,16,17
The gold standard for melanoma detection has always been to perform a biopsy and assess the sample histopathologically.18, 19 However, non-invasive techniques can help clinicians avoid biopsies especially when attempting a diagnosis in the pediatric population.2,20 There are many emerging technologies that intend to serve as diagnostic aides in order avoid unnecessary biopsies instead of relying on clinicians' interpretation of potential for malignancy.